Investors Alert: Class Action Lawsuit Filed Against Aardvark Therapeutics Over Securities Fraud Allegations

Legal Action Against Aardvark Therapeutics: What You Need to Know

Aardvark Therapeutics, a clinical-stage biopharmaceutical firm, is currently facing scrutiny as a class action lawsuit has been initiated against the company. This legal action is spearheaded by Hagens Berman Sobol Shapiro LLP, a respected national law firm that specializes in shareholder rights. Investors who purchased shares of Aardvark Therapeutics (NASDAQ: AARD) during its initial public offering (IPO) around February 13, 2025, and through May 14, 2026, are urged to pay attention, as they may be eligible to join the class action. The lawsuit pertains to allegations of securities fraud, which could potentially leave many investors with substantial losses.

Case Overview

The lawsuit alleges that Aardvark Therapeutics made significant misstatements and failed to disclose key information regarding its drug candidate ARD-101, which was designed to treat conditions associated with Prader-Willi Syndrome (PWS). According to the complaint, the company reportedly misled investors about the safety and efficacy profile of ARD-101 by failing to disclose that it was less safe than previously communicated. Specifically, the lawsuit claims that concerning cardiac observations, like QRS prolongation, arose during trials, alarming the clinical community and leading to unexpected halts in the study.

On February 27, 2026, Aardvark announced it was pausing its Phase 3 HERO trial due to these unexpected cardiac issues found during a safety monitoring exercise. This announcement caused Aardvark’s stock to drop dramatically—by more than 56%—in a single day. Furthermore, on May 14, 2026, the U.S. Food and Drug Administration (FDA) imposed a full clinical hold on Aardvark's investigational new drug application, compelling the company to suspend ongoing studies, including the crucial HERO trial and its open-label extension. This led to an additional 32.1% decline in the company's stock price.

Potential Impact on Investors

As the investigation progresses, it becomes increasingly vital for affected investors to understand their rights and the actions they can take. Aardvark investors who suffered financial losses are encouraged to contact the legal team of Hagens Berman to discuss their eligibility to serve as lead plaintiffs in the class action. The deadline for interested parties to be considered as lead plaintiffs is October 13, 2026.

Reed Kathrein, the partner leading the investigation, commented on the situation, stating that investors have a right to be informed of the true safety and efficacy of drug candidates. In his view, the alleged omissions by Aardvark not only misled investors but also compromised their financial interests.

To aid in the investigation, whistleblowers with non-public information about Aardvark Therapeutics may also reach out to Hagens Berman, as they may be eligible for significant rewards through the SEC Whistleblower program.

Conclusion

The class action lawsuit against Aardvark Therapeutics represents a significant event in the landscape of securities fraud and corporate transparency. As the case unfolds, investors are encouraged to stay informed and proactive in safeguarding their investments. Those interested in participating or seeking further information should reach out to Hagens Berman before the impending October deadline. By engaging with committed legal professionals, investors can better navigate the complexities of this lawsuit and work towards potential recovery options.

For more details, investors should visit Hagens Berman's official website or call their office at 844-916-0895 to learn about their rights and options moving forward.